Mathilde Grande
7 Papers
9 Citations
Mathilde Grande is an academic researcher. The author has contributed to research in topics: Health technology & Medicine. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment.
Etienne Lengliné,Julien Peron,Antoine Vanier,François Gueyffier,Serge Kouzan,Patrick Dufour,Bernard Guillot,Hugues Blondon,Michel Clanet,Pierre Cochat,Françoise Degos,Sylvie Chevret,Mathilde Grande,Jade Putzolu +13 more
TL;DR: In this article, an interdisciplinary panel was convened on behalf of the Transparency Committee of the French National Authority for Health to clarify an approach designed to guarantee a transparent, reproducible, and fair assessment of histology-agnostic treatments for reimbursement by French National Health Insurance Fund.
36
Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).
Nicolas Albin,Frédéric Chassagnol,Jean-François Bergmann,Lotfi Boudali,Olivier Blin,Thibault de Chalus,Estelle Fruchet,Mathilde Grande,Françoise Grudé,Natalie Hoog-Labouret,Céline Kauv,Frédéric Lavie,Claire Le Jeunne,Fabrice Meillier,Brigitte Pouletty-Lefebvre,Anne-Céline Richard,Benjamin Mazaleyrat,Adrien Monard +17 more
TL;DR: A number of proposals are presented, which tend to favor the implementation of clinical trials on territory, especially the early phases, a wider access to innovations by favoring early access programs and setting up a process called "autorisation temporaire d'utilisation d'extension" (ATUext) that make it possible to prescribe a medicinal product even if the latter has a marketing authorisation in another indication.
6
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy
Elaine Julian,Mira Pavlovic,Oriol Solà-Morales,F. Gianfrate,Mondher Toumi,Heiner C. Bucher,Christian Dierks,Wolfgang Greiner,Peter G. M. Mol,Jean-François Bergmann,Tomas Salmonson,Ansgar Hebborn,Mathilde Grande,Antonella Cardone,Jörg Ruof +14 more
TL;DR: In this article , four key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent and consistent management of related processes.
Accès précoce aux produits de santé en France : des avancées majeures du CSIS (Conseil stratégique des industries de santé) à concrétiser (modalités, réglementations, financements).
Nicolas Albin,Frédéric Chassagnol,Jean-François Bergmann,Lotfi Boudali,Olivier Blin,Thibault de Chalus,Estelle Fruchet,Mathilde Grande,Françoise Grudé,Natalie Hoog-Labouret,Céline Kauv,Frédéric Lavie,Claire Le Jeunne,Fabrice Meillier,Brigitte Pouletty-Lefebvre,Anne-Céline Richard,Benjamin Mazaleyrat,Adrien Monard +17 more
TL;DR: Dans le present atelier, nous declinons un certain nombre of propositions, notre approche se veut pragmatique avec un souci permanent d’acces securise des patients aux medicaments et de simplification des procedures reglementaires.
4
Access and price of cancer drugs: What is happening in France?
Mathilde Grande,Judith Fernandez,Jade Putzolu,Sorin Stanel,Margaret Galbraith,Chantal Belorgey,Nicolas Albin,Loïc Guillevin,Anne d'Andon +8 more
TL;DR: The French National Authority for Health (HAS) is responsible for health technology assessment (HTA), providing opinion on drugs for reimbursement and pricing purposes.
4